Research programme: antibody drug conjugates - Pyxis oncology
Latest Information Update: 01 Sep 2023
Price :
$50 *
At a glance
- Originator Pyxis Oncology
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 25 Aug 2023 Early research in Haematological malignancies in USA (Parenteral) (Pyxis oncology pipeline, August 2023)
- 25 Aug 2023 Early research in Solid tumours in USA (Parenteral) (Pyxis oncology pipeline, August 2023)
- 18 Mar 2021 Pyxis Oncology in-licenses antibody drug conjugate platform and technology from Pfizer